ARTICLE | Finance
Value verification
Biotech specialists see a handful of data milestones driving returns in 4Q11
October 3, 2011 7:00 AM UTC
Buysiders are looking for strong data from a handful of high-profile compounds to drive their returns this quarter and to improve their 2011 performance.
Infectious disease company Pharmasset Inc. provided a head start on the last day of 3Q when the American Association for the Study of Liver Diseases (AASLD) published an abstract for Phase IIb data from the company's ELECTRON study for PSI-7977 to treat HCV...